Overview
Melanotan 1 and Melanotan 2 are two structurally related synthetic melanocortin peptides that have been studied extensively in pigmentation research, yet they differ significantly in receptor selectivity and research applications. Understanding these distinctions is fundamental for researchers working in melanocortin receptor biology. This comparison examines their structural differences, receptor profiles, and the domains where their research applications diverge.
For general context on peptide research, consult our guide on what peptides are and review our quality and purity standards.
Melanotan 1 in Research
Melanotan 1 (MT-1), also known as afamelanotide, is a linear synthetic analogue of alpha-melanocyte-stimulating hormone (alpha-MSH). Its development at the University of Arizona in the 1980s and 1990s was directed toward creating a more stable and potent melanocortin compound. The key structural modification relative to natural alpha-MSH is the substitution of norleucine for methionine at position 4 and D-phenylalanine at position 7, resulting in a peptide with greater resistance to enzymatic degradation and higher melanocortin receptor potency.
MT-1’s receptor selectivity profile is its defining research characteristic. It exhibits preferential binding to the melanocortin 1 receptor (MC1R) — the receptor expressed predominantly on melanocytes and responsible for eumelanin production. This selectivity made MT-1 a focused tool for pigmentation biology research.
MT-1 has undergone the most advanced clinical development of the two compounds. Afamelanotide has been investigated in clinical trials for erythropoietic protoporphyria (EPP), a rare genetic disorder characterized by extreme photosensitivity. It received regulatory approval in Europe for this specific indication. This clinical context distinguishes MT-1 as having the more established and narrowly targeted regulatory and research profile.
Key MT-1 research domains:
- MC1R-selective agonism studies
- Eumelanin synthesis and photoprotection research
- Erythropoietic protoporphyria clinical investigations
- Melanocyte biology and pigment cell physiology
Our Melanotan 1 compound guide provides additional mechanistic background. Research-grade MT-1 is available at our Melanotan MT-1 10mg product page.
Melanotan 2 in Research
Melanotan 2 (MT-2) is a cyclic heptapeptide — its cyclization via a lactam bridge between the aspartate and lysine residues at positions 4 and 10 distinguishes it structurally from the linear MT-1. This cyclization was introduced to improve stability and receptor binding characteristics, but it also broadened the compound’s receptor interaction profile beyond MC1R.
MT-2’s receptor binding profile is the critical differentiator: it binds not only MC1R but also MC3R, MC4R, and MC5R with varying affinities. This broader melanocortin receptor engagement is what drives MT-2’s wider and more complex research profile compared to the MC1R-selective MT-1.
The melanocortin receptors targeted by MT-2 and their primary research-studied functions:
- MC1R: Melanocyte pigmentation (shared with MT-1)
- MC3R: Energy homeostasis, feeding behaviour regulation research
- MC4R: Hypothalamic feeding and energy expenditure studies; sexual function research
- MC5R: Exocrine gland function investigations
MT-2’s activity at MC4R in particular has generated significant research interest, as MC4R is expressed in the hypothalamus and has been studied in the context of appetite regulation and energy balance. This mechanistic breadth has driven MT-2 to appear in a wider variety of preclinical research programs beyond simple pigmentation studies.
See our Melanotan 2 compound guide for detailed receptor pharmacology information. Our Melanotan MT-2 10mg is available for qualified researchers.
Receptor Profile Comparison
The structural and receptor binding differences between MT-1 and MT-2 are the central scientific distinction:
| Feature | Melanotan 1 (MT-1) | Melanotan 2 (MT-2) |
|---|---|---|
| Structure | Linear peptide | Cyclic heptapeptide |
| MC1R activity | High (primary target) | Yes (one of several targets) |
| MC3R activity | Low | Yes |
| MC4R activity | Low | Yes (significant) |
| MC5R activity | Low | Yes |
| Research selectivity | Narrow (pigmentation focused) | Broad (multi-receptor profile) |
| Clinical advancement | Highest (EPP approval in EU) | Less advanced clinical program |
Research Applications
The receptor selectivity difference drives distinct research utility for each compound:
MT-1 as a research tool: MT-1’s MC1R selectivity makes it the preferred compound for studies requiring clean MC1R agonism. Researchers investigating melanocyte biology, eumelanin synthesis pathways, or the MC1R signalling cascade can use MT-1 with greater mechanistic confidence that observed effects are MC1R-mediated. Its clinical advancement in EPP also provides a richer clinical literature base for researchers working on rare photosensitivity disorders.
MT-2 as a research tool: MT-2’s broader receptor profile makes it valuable for researchers studying the melanocortin system as a whole, or for investigations specifically targeting MC4R-mediated pathways. The compound’s multi-receptor engagement produces a more complex pharmacological picture, which is both a research challenge and an opportunity depending on the study design.
For researchers choosing between the two, the decision should be driven by the receptor target of interest. MC1R-specific studies warrant MT-1; broader melanocortin receptor investigations — particularly those involving MC4R — typically employ MT-2.
Explore our Research Hub for additional peptide science resources. Consult our peptide storage guide for proper compound handling and reconstitution protocols. To view all available compounds, browse our research catalog.
For research purposes only. Not intended for human use. This content is educational and does not constitute medical advice.